Serono-Ono co-co- for go/no-go on so-so onco Stimuvax
This article was originally published in Scrip
Merck Serono and Ono Pharmaceutical have signed a licence agreement providing Ono with co-development and co-marketing rights to Merck's investigational therapeutic cancer immunotherapy Stimuvax in Japan. Stimuvax (BLP25 liposome vaccine), which is designed to stimulate the body's immune system to target cancer cells that express the tumour antigen MUC-1, is in Phase III for the treatment of patients suffering from non-small cell lung cancer. Merck had originally obtained the exclusive worldwide licensing rights from Oncothyreon.
You may also be interested in...
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.
Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.